TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06566456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The puncture site is within 2-4 cm above the second wrist transverse crease
Description: The ultrasound-guided radial artery puncture site is within 2-4 cm above the second wrist transverse crease, where the clearest radial artery image can be obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The puncture site is within 0-1.9 cm above the second wrist transverse crease
Description: The ultrasound-guided radial artery puncture site is within 0-1.9 cm above the second wrist transverse crease, where the clearest radial artery image can be obtained.
Study: NCT04301089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pico G2 4K Headset with Applied VR software
Description: headset worn at time points defined in study
Study: NCT05171387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide 600 mg twice daily
Description: The participants will take 2 tablets (300 mg each tablet) of study treatment (darolutamide) orally bid at about 12 hour intervals.
Study: NCT06221371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTNK-tPA
Description: rhTNK-tPA (0.25 mg/kg, maximum dose 25mg) is given as a single, intravenous bolus (injection over 5 to 10 seconds) immediately upon randomization. EVT should be performed as soon as possible after rhTNK-tPA administration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: direct EVT
Description: During the study period, NMPA-approved stents are permitted. EVT included thrombectomy with stent retrievers, thromboaspiration, intraarterial thrombolysis, balloon angioplasty, stenting, or a combination of these approaches at the discretion of the interventional team.
Study: NCT04879706

Intervention type: OTHER
Intervention: None planned
Description: No intervention planned
Study: NCT05415436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propofol slow administration
Description: Propofol will be slowly administered over 120 seconds by anesthesia provider
Study: NCT06407492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leech
Description: The leeches used in the treatment were obtained from people producing in culture media. Leech therapy was applied to the patients once a week. Before coming to treatment, patients were warned not to use perfume or apply any chemicals on the skin. While no skin preparation was made before the treatment, in patients with cold legs, the area where the leech would be applied was heated to ensure easy adhesion of the leech. The leeches left on their own after approximately 40 to 38 minutes, but the leeches that did not release on their own until 60 minutes were removed by scraping them from the skin with the help of a gauze. The leeches used in the treatment were used only once and the used ones were disposed of by throwing them into medical waste bags. After the leeches were removed from the patient, the wound was covered with a printed bandage. Patients were instructed to remove the bandage after 10-12 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.
Study: NCT05719870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational training
Description: The intervention will include: first, educational training of patients/caregivers at hospital discharge by a multidisciplinary team; second, after hospital discharge, a phone recall on the prescribed therapies and a one-week phone consultant service managed by a geriatrician, supported by the multidisciplinary team, to address potential concerns on prescribed treatments.
Study: NCT04882293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg / Fenofibrate 160 mg in fixed dose
Description: 1 tablet once a day, 20 mg /160 mg, Orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin (Lipitor ®)
Description: 1 tablet once a day, 20 mg, Orally
Study: NCT05265182

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.
Study: NCT06407492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy applications were performed. Physiotherapy applications were performed with transcutaneous electrical nerve stimulation, hotpack and ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: In this taping technique, skin color, 5cmX5m kinesio tape material was used. Again, the patient standing upright will be prepared in terms of clothing and skin. The standing patient will then be asked to lean forward. Taping will be done using a special muscle technique for this group. When applying tape to the right paravertebral region, first the lower end of the tape will be adhered 7 cm below the sacroiliac joint, at the level of the paravertebral muscles. When applying tape to the left paravertebral region, the same procedure will be done in reverse as on the right, and the tape will not be stretched at all. The third tape will be applied to the patient who is standing upright and bending slightly forward, passing over the sacroiliac joints and parallel to the ground, with the tape stretched by 25%.
Study: NCT05339815

Intervention type: DEVICE
Intervention: SMR shoulder arthroplasty
Description: Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres

Intervention type: DEVICE
Intervention: SMR shoulder arthroplasty
Description: Data collection of population that underwent a reverse shoulder arthroplasty performed with SMR 36-mm CoCrMo versus 40-mm cross-linked UHMWPE glenospheres
Study: NCT06476704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of L-TC
Description: Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: HFRT alone
Description: HFRT : 30 Gy in 5 fractions of 6 Gy.~1 fraction per day, 5 days per week.
Study: NCT05050305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally
Study: NCT05686460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ice massage
Description: After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. The Hegu point of the participating students was detected with the acupuncture point finder. Ice cubes whose dimensions were 2x2x2 cm were wrapped with gauze and placed in a plastic bag. Vaseline® jelly was spread on the application area. The application applied 2 minutes of ice massage 7 times at 15-second intervals. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test).~On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music medicine
Description: After the students who met the sample selection criteria applied Student Information Form. On the first day of the participating students' menstruation, prior to the application (when the pain started), the Visual Analogue Scale (VAS), General Comfort Questionnaire (GCQ) and Dysmenorrhea Follow-up Form were filled in at the pre-test. Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The volume of the music was adjusted based on the verbal feedback or facial expressions of the students. The participants' pain levels were assessed three times, as soon as the application was over, 30 and 60 minutes after the application (Post-test). On the second day of menstruation, the participants were asked to fill in the VAS, GCQ, and Effects of Dysmenorrhea Scale (EDS).
Study: NCT06274619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A Memphis 37
Description: RSV A Memphis 37 challenge agent
Study: NCT06172738

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the left atrial appendage closure through surgery.
Description: Surgical closure of the left atrial appendage during the set of an elective open heart surgery with the inclusion criteria fulfilled.
Study: NCT06411522

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash containing 0.12% CHX (Chlorhexidine)
Description: Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.2% CHX mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthwash containing 0.05% CHX (Chlorhexidine) and 0.05% CPC (Cetylpyridinium Chloride)
Description: Following the execution of a full mouth periodontal chart, the delivery of oral hygiene instructions and motivation and a session of full mouth ultrasonic debridement, patients, according to the allocation group, will receive a 0.05% CHX + 0.05% CPC mouthwash. Patients will be instructed to use the delivered mouthwashes twice a day (15 ml for 30 seconds).
Study: NCT06494501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
Study: NCT06548503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Si.Pi.Mi product
Description: Assumption of the product as detailed in the protocol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assumption of placebo
Study: NCT05171387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: Androgen deprivation therapy (ADT) is a treatment that commonly used to lower the amount of hormones called androgens in the body.
Study: NCT04750473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scan
Study: NCT04656301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A single dose of psilocybin 25 mg will be administered orally in the Biological Studies Unit of New York State Psychiatric Institute
Study: NCT06501807

Intervention type: DRUG
Group type: OTHER
Intervention: Biologic treatments available in Chronic Rhinosinusitis with Nasal Polyps (dupilumab, mepolizumab and benralizumab according to their marketing approval).
Description: Drug prescription according to their marketing approval (subcutaneously, every month or every two weeks).
Study: NCT04750473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV
Study: NCT05035745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Patients will be treated with Talazoparib daily on a 4 weekly cycle (28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients will be treated with Selinexor once per week (3 out of 4 weeks), on a 4 weekly cycle (28 days)
Study: NCT04750473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study: NCT03959046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GIST
Description: The GIST intervention will train physicians in an alternative way of communicating with their patients.
Study: NCT04626609

Intervention type: OTHER
Intervention: Biopsy samples
Description: Esophageal mucosal biopsies are collected during gastroscopy

Intervention type: OTHER
Intervention: Biopsy samples
Description: Esophageal mucosal biopsies are collected during gastroscopy

Intervention type: OTHER
Intervention: Biopsy samples
Description: Esophageal mucosal biopsies are collected during gastroscopy

Intervention type: OTHER
Intervention: Blood samples
Description: Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes

Intervention type: OTHER
Intervention: Blood samples
Description: Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes

Intervention type: OTHER
Intervention: Blood samples
Description: Blood will be drawn by venipuncture into citrate- or ethylenediaminetetraacetic acid (EDTA)-containing vacutainer tubes and into serum tubes
Study: NCT05118035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled ECG-based Screening Tool
Description: Primary care clinicians in the intervention group had access to the report, which shows the risk prediction results for each patients. Moreover, the clinicians will recieve a short message when patients with a high risk ECG identified by AI.
Study: NCT06568042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3848575
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3848575
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3848575
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05665530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT2527
Description: PRT2527 will be administered by intravenous infusion once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT2527
Description: PRT2527 will be administered by intravenous infusion once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT2527
Description: PRT2527 will be administered by intravenous infusion once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT2527
Description: PRT2527 will be administered by intravenous infusion once weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib will be provided in capsules for oral administration once or twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be provided in tablet for oral administration once daily
Study: NCT04887350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Student-Senior Isolation Prevention Partnership (SSIPP)
Description: The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Student-Senior Isolation Prevention Partnership (SSIPP)
Description: The Student-Senior Isolation Prevention Partnership partners medical students with older adults in the community to provide social support and connection through regular phone calls. The goal of SSIPP is to reduce rates of anxiety, depression, and loneliness, while fostering resilience among seniors in our communities. This intervention will be delivered by phone to study participants once a week for a 30-60 minute session over a 12-week period.
Study: NCT04451044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips SyncVision system with Philips pressure wires
Description: Intent to use physiologically-guided PCI using the Philips SyncVision system for determining the PCI strategy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard of care angiographically-guided PCI
Description: Intent to use PCI standard of care angiographically-guided PCI for determining the PCI strategy
Study: NCT04887350

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Solving Therapy (PST).
Description: Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Problem Solving Therapy (PST).
Description: Problem Solving Therapy is a psychotherapeutic intervention that teaches community members to identify and clarify problems at hand, set clear, achievable goals, brain-storm solutions to the problem, select their preferred solution, implement this solution, and evaluate the outcomes. This intervention will be delivered by a trained healthcare professional by phone to study participants once a week for a 30-60 minute session over a 12-week period.
Study: NCT05978219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine Tablets
Description: Mirtazapine tablet form, orally, once or twice daily, 15-45 mg
Study: NCT06077162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Nutrition Education Classes
Description: Diabetes nutrition education offered by registered dietitian in group-based classes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Nutrition Education Classes
Description: Diabetes nutrition education offered by registered dietitian in group-based classes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Food Security Resource
Description: Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Food Security Resource
Description: Participants offered security resource which is a $30.00 Aldi (grocery store) gift card provided weekly for 12 weeks.
Study: NCT06010004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally
Study: NCT06166576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablative radioembolization
Description: The interventional radiologist utilizes a pre-test with 99mTc-MAA SPECT-CT and cone-beam CT for procedural planning. For tumors confined to a single segment, the treatment area is planned to receive a radiation dose of over 400 Gy using the single-compartment MIRD technique. For tumors extending beyond a single segment, the multi-compartment MIRD technique is used to plan a radiation dose of 700 Gy (± 20%) to the tumor. The upper limit for the estimated lung dose is set at 25 Gy, and the upper limit for the perfused non-tumoral liver dose is 250 Gy. In cases where tumors extending beyond a single segment cannot receive the planned dose of 700 Gy (± 20%) due to limits on lung or normal liver dose, the plan is adjusted to deliver the maximum dose to the tumor within the permissible range for lung and normal liver doses. Radioembolization is typically performed in a single session, and any methods not mentioned here should follow the instructions for use of TheraSphere.
Study: NCT04608916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Using surgical diathermy to make skin incision
Description: Using surgical diathermy to make skin incision during shoulder arthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Using scalpel blade to make skin incision
Description: Using scaple blade to make skin incision during shoulder arthroplasty
Study: NCT04683796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100% Autologous platelet rich plasma
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes containing 4 ml of 3.2% buffered citrate acid for anticoagulation. Tubes will be centrifuged at 350 g for 10 minutes at 20 C. The two upper layers of the centrifuged blood, the plasma and the superficial buffy coat, will be separated in a sterile manner under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% Autologous serum
Description: Patients' blood (36 ml per tube) will be collected in three 50-ml sterile centrifuge tubes. The tubes will be left standing in an upright position for 1-2 hours to enable blood clot formation at room temperature (18-25 C). The tubes will be centrifuged at 3000 g for 30 minutes at 20 C. The supernatant serum will be aseptically transferred into a sterile syringe to enable filtration through a 0.2 µm pore size membrane filter under a laminar air flow hood. A 1.5 ml aliquot of both final blood products will be transferred into identical opaque eye drop bottles, labelled name, hospital number, dated and sealed.
Study: NCT05798143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
Study: NCT04827758

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening and diagnostic tests for sarcopenia
Description: All of the following tests and questionnaires will be performed :~* SARC-F questionnaire,~* measurement of muscle strengh by a grip test,~* measurement of muscle mass by impedancemetry (ASM/size2),~* 4-meter walking speed test,~* Timed-Up and Go (TUG) test,~* ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) questionnaires.
Study: NCT01280071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminophylline